Teriparatide: Building Stronger Bones for High-Risk Steroid Users
Teriparatide: Building Stronger Bones for High-Risk Steroid Users
The Bone Builder
For some people at very high risk of fractures from steroid use, a medication called teriparatide offers a unique approach. Unlike other osteoporosis drugs that slow bone loss, teriparatide actually stimulates new bone growth.
Contents
- How It Works
- Who Might Benefit?
- Treatment Details
How It Works
Teriparatide is a synthetic form of parathyroid hormone. When given in small, daily doses, it activates bone-building cells called osteoblasts. This leads to increased bone density and improved bone structure. Think of it as giving your skeleton's construction crew a powerful energy boost.
Who Might Benefit?
Doctors typically reserve teriparatide for people at the highest risk of fractures from steroid use. This includes those with very low bone density, a history of fractures, or who haven't responded well to other treatments. It's particularly useful for postmenopausal women and men over 50 who need long-term steroid therapy.
Treatment Details
Teriparatide is given as a daily injection under the skin, usually for up to two years. After treatment, most people switch to a bisphosphonate to maintain the gains in bone density. While effective, teriparatide is more expensive than other options and requires daily injections, which may not be suitable for everyone.
FAQs
Does teriparatide have side effects?
Common ones include nausea, dizziness, and leg cramps.
Can I take teriparatide if I've had radiation therapy?
It's usually not recommended due to a potential increased risk of bone cancer.
How quickly does teriparatide work?
Significant improvements in bone density are often seen within 6-12 months.
A Powerful Option
For those at highest risk, teriparatide offers a unique way to rebuild bone and reduce fracture risk.
Additional References
- Saag KG, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.
- Langdahl BL, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.